Apparently, Arena's collaboration with New Merck -- on a new atherosclerosis drug candidate called MK-1903 -- is at an end.
Per Reuters reporting, tonight:
. . . .Merck's decision to pull out from developing MK-1903 came after a mid-stage clinical trial conducted on patients with dyslipidemia failed to meet the primary objective for efficacy, Arena said in a statement.
Merck indicated that the increase of "HDL" or so-called good cholesterol relative to a placebo did not meet the trial's pre-specified objective for efficacy, but did not tie its decision to any safety concerns, Arena said. . . .